John Galvin, a Rhode Island retiree, put off a $3,000 colonoscopy because he couldn't afford it before Medicare kicked in at 65. That is not a personal finance anecdote. That is a delayed cancer screening in a population where colorectal cancer is both common and, when caught early, highly survivable. The delay is the harm.
Over two-thirds of U.S. adults receive unaffordable medical bills. The national medical debt total sits at $220 billion. Half of Americans cannot cover a $500 emergency, which means a single hospitalization with a $10,000 deductible doesn't just create debt; it creates a decision tree where every subsequent medical need gets weighed against financial survival. The downstream health consequences of that calculus are not theoretical.
The Mechanism Is Not Complicated
Medical debt harms health through 2 documented pathways. First, it causes deferred care: patients with outstanding medical debt are measurably more likely to skip dental visits, mental health appointments, and follow-up care for chronic conditions. Second, financial stress activates the same physiological stress response as any other chronic threat, elevating cortisol, disrupting sleep, and worsening cardiovascular and metabolic outcomes. Eva Stahl, VP of Policy at Undue Medical Debt, put it plainly: erasing debt reduces patient anxiety and stress, which improves health outcomes. That is not a wellness claim. That is a mechanistic description of how financial pressure translates into biological harm.
The evidence for the deferred care pathway is strong. A 2024 University of Michigan poll identified medical costs as the top concern for adults over 50, and 2026 data shows some 60-year-olds paying $2,460 per month in premiums after ACA subsidies expired, with $2,700 deductibles on top. The predictable result: people delay colonoscopies and CT scans until Medicare eligibility. Galvin said it himself: "I put it off." Multiply that by millions of people in the same insurance gap and you have a public health problem, not a series of individual choices.
I will grant the counterargument its due: debt relief programs don't fix the underlying pricing dysfunction that generates the debt. That is true. Undue Medical Debt has relieved over $25 billion for more than 15 million people, and the Atrius Health Equity Foundation just announced a $42.3 million initiative erasing debt for nearly 30,000 Massachusetts residents. These are meaningful interventions. They are also, structurally, a bucket brigade in front of a burning building.
Relief Works. That Is the Point.
Here is where I want to be precise about what the evidence actually shows. Patients who receive debt relief report improved physical well-being and better credit outcomes. That is a correlation, not a randomized controlled trial. The methodological limitation is real. But the biological plausibility is high, the deferred-care mechanism is well-established, and the direction of effect is consistent across multiple data sources. When the evidence points the same direction from multiple angles, I don't wait for a perfect RCT before drawing a conclusion.
The policy implication is specific: Congress should fund debt relief at scale as a public health expenditure, not a charitable gesture. The math from Undue's model, roughly $1 donated abolishes $100 in debt, makes this one of the more cost-efficient health interventions available. Sentara Healthcare reported $185 million in uncompensated care in 2025. That money is already being spent. The question is whether it gets spent before or after the delayed colonoscopy becomes a stage III diagnosis.
Galvin's colonoscopy is still waiting. The cancer, if it's there, is not.
